Non-Injectable Insulin Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Insulin is a hormone produced in the human exocrine gland, located behind the stomach. It permits the body to use glucose for energy. Non-injectable insulin keeps food in the stomach longer, increases insulin when one eats and lowers the amount of glucose released by the liver. Vomiting, decreased appetite, nausea are some of the drawbacks of this medication. So far, only two non-injectable insulins are available in the market, named Exubera and Afrezza. Exubera was eliminated from the market due to its low sales. Afrezza is the only non-injectable insulin in market that is delivered by inhalation.
MARKET DYNAMIC
Factors driving the non-injectable insulin market growth are no requirement of training while taking medication, rapid absorption, and handy devices. However, the adoption rate in patients, and regulatory bodies is likely to hamper the development of the market. Moreover, the patient-friendly device and patient compliance are further expected to create growth opportunities the non-injectable insulin market.

MARKET SCOPE

The "Non-Injectable Insulin Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of non-injectable insulin market with detailed market segmentation by product, by type, and distribution channel. The non-injectable insulin market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in non-injectable insulin market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The non-injectable insulin market is segmented on the basis of product, by type, and distribution channel. On the basis of product, the market is categorized as pills, sprays and others. On the basis of type, the market is categorized as synthetic insulin, and semi synthetic insulin. On the basis of distribution channel, the market is categorized as hospital pharmacies, online pharmacies, and drug stores.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the non-injectable insulin market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The non-injectable insulin market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting non-injectable insulin market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the non-injectable insulin market in these regions.

MARKET PLAYERS

The report covers key developments in the non-injectable insulin market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from non-injectable insulin market are anticipated to have lucrative growth opportunities in the future with the rising demand for non-injectable insulin in the global market. Below mentioned is the list of few companies engaged in non-injectable insulin market.

The report also includes the profiles of key players in non-injectable insulin market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years.

•   Midatech Pharma Plc
  
•   Shreya Life Sciences Pvt. Ltd.
  
•   Boston Therapeutics, Inc.
  
•   Coromed, Inc.
  
•   Diabetology Ltd.
  
•   Emisphere Technologies, Inc.
  
•   Oramed Pharmaceuticals, Inc.
  
•   Diasome Pharmaceuticals, Inc.
  
•   Generex Biotechnology Corp.
  
•   Biodel, Inc. (Albireo Ltd.)
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Non-Injectable Insulin Report Scope